BBCMF (Lir Life Sciences) Net-Net Working Capital: $0.02 (As of Jan. 2026)


BBCMF Lir Life Sciences Corp BBCMF
15 GF Score
Price $0.05
View Full Analysis

What is Lir Life Sciences Net-Net Working Capital?

Lir Life Sciences BBCMF 15 Net-Net Working Capital is $0.02 as of Jan. 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 859 Biotechnology companies, Lir Life Sciences ranks worse than 76.25% on this metric.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Lir Life Sciences's Net-Net Working Capital for the quarter that ended in Jan. 2026 was $0.02.

The industry rank for Lir Life Sciences's Net-Net Working Capital or its related term are showing as below:

BBCMF's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 5.5
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Lir Life Sciences  (OTCPK:BBCMF) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Lir Life Sciences Net-Net Working Capital Related Terms


Lir Life Sciences Net-Net Working Capital Historical Data

* Premium members only.

The historical data trend for Lir Life Sciences's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lir Life Sciences Net-Net Working Capital Chart

Lir Life Sciences Annual Data
Trend Apr24 Apr25
Net-Net Working Capital
0.00 0.00

Lir Life Sciences Quarterly Data
Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Net-Net Working Capital Get a 7-Day Free Trial 0.00 0.00 -0.01 0.04 0.02

BBCMF vs VRTX, REGN, ALNY: Net-Net Working Capital Comparison

For the Biotechnology subindustry, Lir Life Sciences's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lir Life Sciences Price-to-Net-Net-Working-Capital vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lir Life Sciences's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Lir Life Sciences's Price-to-Net-Net-Working-Capital falls into.


BBCMF
15GF Score
Lir Life Sciences Corp BBCMF
Net-Net Working Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lir Life Sciences Net-Net Working Capital Calculation

Lir Life Sciences's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Apr. 2025 is calculated as

Net-Net Working Capital(A: Apr. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.087+0.75 * 0+0.5 * 0-0.145
-0-0)/27.867
=-0.00

Lir Life Sciences's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jan. 2026 is calculated as

Net-Net Working Capital(Q: Jan. 2026 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.669+0.75 * 0+0.5 * 0-0.057
-0-0)/27.867
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

What does a Net-Net Working Capital of $0.02 mean?
Lir Life Sciences (BBCMF) has a Net-Net Working Capital of $0.02 as of Jan. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Lir Life Sciences According to the industry distribution chart, Lir Life Sciences ranks #655 out of 859 companies in the Biotechnology industry, placing it in the top 76.3%.
Is Lir Life Sciences' Net-Net Working Capital too high?
Lir Life Sciences' current Net-Net Working Capital is $0.02. The Biotechnology industry median Net-Net Working Capital is 5.50. Lir Life Sciences' value of $0.02 is 99.6% below this industry median. Based on the distribution chart, Lir Life Sciences ranks #655 out of 859 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' Net-Net Working Capital compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #655 out of 859 companies for Net-Net Working Capital. This places Lir Life Sciences in the lower half of its industry. The industry median Net-Net Working Capital is 5.50. Lir Life Sciences' value of $0.02 is 99.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.50, based on 859 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lir Life Sciences's current Net-Net Working Capital of $0.02 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Lir Life Sciences For the Biotechnology industry, the median Net-Net Working Capital is 5.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current Net-Net Working Capital is $0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current Net-Net Working Capital of $0.02. The current Net-Net Working Capital is $0.02 and 99.6% below the Biotechnology industry median of 5.50. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current Net-Net Working Capital is $0.02 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lir Life Sciences Business Description

Other Exchanges N790:GermanySKNY:Canada
Address 505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score

Get the complete analysis for BBCMF

Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.05
Price